ALX Oncology Holdings Inc. (NASDAQ:ALXO) Given Average Rating of “Moderate Buy” by Brokerages

Shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO) have been given an average rating of “Moderate Buy” by the six research firms that are currently covering the firm, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 1 year price target among analysts that have covered the stock in the last year is $8.50.

A number of equities analysts have issued reports on the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of ALX Oncology in a report on Wednesday, December 18th. Jefferies Financial Group downgraded ALX Oncology from a “buy” rating to a “hold” rating and lowered their price objective for the company from $12.00 to $2.00 in a research note on Thursday. Finally, HC Wainwright reiterated a “buy” rating and issued a $25.00 price objective on shares of ALX Oncology in a report on Wednesday, December 18th.

Insider Buying and Selling at ALX Oncology

In other news, Director Rekha Hemrajani bought 30,000 shares of the firm’s stock in a transaction on Monday, December 2nd. The stock was acquired at an average price of $1.55 per share, with a total value of $46,500.00. Following the transaction, the director now owns 33,000 shares of the company’s stock, valued at $51,150. This trade represents a 1,000.00 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 33.40% of the company’s stock.

Institutional Investors Weigh In On ALX Oncology

A number of institutional investors have recently modified their holdings of ALXO. Barclays PLC raised its stake in ALX Oncology by 243.6% during the third quarter. Barclays PLC now owns 59,502 shares of the company’s stock worth $107,000 after buying an additional 42,185 shares during the last quarter. XTX Topco Ltd bought a new position in shares of ALX Oncology in the 3rd quarter worth about $578,000. Wellington Management Group LLP lifted its stake in shares of ALX Oncology by 15.2% in the 3rd quarter. Wellington Management Group LLP now owns 167,831 shares of the company’s stock valued at $305,000 after purchasing an additional 22,114 shares during the period. Verition Fund Management LLC boosted its position in shares of ALX Oncology by 308.4% during the 3rd quarter. Verition Fund Management LLC now owns 133,025 shares of the company’s stock valued at $242,000 after purchasing an additional 100,454 shares in the last quarter. Finally, Walleye Capital LLC boosted its position in shares of ALX Oncology by 110.3% during the 3rd quarter. Walleye Capital LLC now owns 230,875 shares of the company’s stock valued at $420,000 after purchasing an additional 121,113 shares in the last quarter. 97.97% of the stock is owned by institutional investors.

ALX Oncology Stock Up 9.5 %

Shares of ALXO opened at $1.62 on Monday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 4.82 and a current ratio of 4.82. ALX Oncology has a 52 week low of $1.19 and a 52 week high of $17.83. The stock has a market capitalization of $85.44 million, a price-to-earnings ratio of -0.54 and a beta of 1.04. The stock has a fifty day moving average of $1.49 and a 200-day moving average of $3.29.

About ALX Oncology

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.